We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The company also temporarily stopped all sales of its approved gene therapy Zynteglo, a treatment for the blood disorder beta thalassemia that uses the same the same lentiviral vector. Read More
A new UK study has found that statins did not have any overall effect on muscle symptoms in patients who had previously reported them when taking the medications, suggesting that statins may not responsible for the muscle pains associated with taking them. Read More
The Pfizer/BioNTech COVID-19 vaccine showed the same effectiveness for all age groups — including individuals over age 60 — confirmed a new study from Israel that included almost 1.2 million individuals. Read More
Pfizer and BioNTech have begun assessing the safety and immunogenicity of a third dose of their COVID-19 vaccine against the coronavirus’ South African mutation and other potential viral variants. Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own. Read More
Fujifilm is betting that Avigan, which inhibits the RNA polymerase enabling the flu virus to replicate, will work against the coronavirus, another RNA virus. Read More
In December, GSK and Sanofi suffered a setback during their phase 1/2 trial, when their vaccine was found to produce only a weak immune response in older patients. Read More
Roughly three-quarters of women enrolled in the trial saw a 50 percent or greater reductions from baseline in menstrual blood loss volume during the last 35 days of treatment. Read More
GlaxoSmithKline (GSK) and Sanofi have launched a phase 2 study evaluating their adjuvanted recombinant COVID-19 candidate, after delaying the trial by more than two months. Read More
Novavax has announced that it has completed enrolling 30,000 participants in its late-stage U.S./Mexico pivotal trial of its COVID-19 vaccine, bringing its recombinant protein-based vaccine hopeful one step closer to potential FDA authorization. Read More
The small-scale trial will include up to 90 healthy adult volunteers age 18 to 30 years who will be exposed to the virus in a controlled setting. Read More
RSS
